loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Lefamulin Acetate

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Lefamulin Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nabriva Tx Expands XENLETA Presence with Excl. Agreement with Er-Kim Pharma
    Nabriva Tx Expands XENLETA Presence with Excl. Agreement with Er-Kim Pharma

    18 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/18/2480937/37424/en/Nabriva-Therapeutics-Expands-XENLETA-lefamulin-Presence-with-Exclusive-Agreement-with-Er-Kim-Pharmaceuticals.html

    GLOBENEWSWIRE
    18 Jul 2022
    Share Share
    Nabriva Begins Enrollment in PI Trial of XENLETA for Cystic Fibrosis
    Nabriva Begins Enrollment in PI Trial of XENLETA for Cystic Fibrosis

    11 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/11/2420431/37424/en/Nabriva-Therapeutics-Announces-First-Patient-Enrolled-in-Phase-1-Trial-of-XENLETA-lefamulin-in-Adult-Patients-with-Cystic-Fibrosis.html

    GLOBENEWSWIRE
    11 Apr 2022
    Share Share
    Nabriva Announces Availability of XENLETA in a 10-Count Oral Pack
    Nabriva Announces Availability of XENLETA in a 10-Count Oral Pack

    11 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/11/2332502/37424/en/Nabriva-Announces-Availability-of-XENLETA-lefamulin-in-a-10-Count-Oral-Pack.html

    GLOBENEWSWIRE
    11 Nov 2021
    Share Share
    Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®
    Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®

    04 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/04/2308286/37424/en/Nabriva-Publishes-Data-Demonstrating-the-Potent-Anti-Inflammatory-Properties-of-XENLETA-lefamulin.html

    GLOBENEWSWIRE
    04 Oct 2021
    Share Share
    Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®
    Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®

    04 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/04/2308286/37424/en/Nabriva-Publishes-Data-Demonstrating-the-Potent-Anti-Inflammatory-Properties-of-XENLETA-lefamulin.html

    GLOBENEWSWIRE
    04 Oct 2021
    Share Share
    Nabriva Therapeutics to Present Data at IDWeek 2021
    Nabriva Therapeutics to Present Data at IDWeek 2021

    24 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/24/2302872/37424/en/Nabriva-Therapeutics-to-Present-Data-at-IDWeek-2021.html

    GLOBENEWSWIRE
    24 Sep 2021
    Share Share